A critical role for mast cells in TLR2-mediated inhibition of tumor growth in vivo (101.24)

• DOI: 10.4049/jimmunol.184.supp.101.24
• Publication Date: 2023-01-01T04:08:47Z
• Authors: Sharon Oldford; Ian Haidl; Mackenzie Howatt; Carlos Leiva; Brent Johnston; Jean Marshall
• Keywords: Cancer Immunotherapy

Abstract Mast cells are abundant surrounding solid tumors where they typically promote angiogenesis and enhance tumor growth metastasis. In the context of infection, mast respond to pathogens via innate immune receptors, including TLR, produce mediators which aid host defense cell recruitment. Some TLR agonists effective in immunotherapy but role their mechanism action is unclear. Using a melanoma model wild-type C57BL/6 deficient KitW-sh/W-sh mice, were shown be crucial for TLR2-agonist (Pam3CSK4) induced inhibition. Activation TLR2 on reversed established pro-tumorigenic role. The inhibitory effects Pam3CSK4 restored mice by local reconstitution with wild-type, not TLR2-deficient cells. Tumor inhibition occurred independent derived TNF cytotoxicity was associated suppression NK T mediated, also observed an LLC1 lung cancer model. This study reveals novel vivo has important implications design immunotherapeutic strategies harnessing functions